Table 4

Baseline immunosuppression characteristics and modification during the infection

Baseline immunosuppression therapyOverall, n (%)No modification, n (%)Reduction, n (%)Discontinuation, n (%)
Single agent
CNIs16 (28)12 (75)2 (12.5)2 (12.5)
 Cyclosporine3 (5)2 (67)01 (33)
 Tacrolimus13 (29)10 (77)2 (15)1 (8)
mTORi2 (4)1 (50)01 (50)
 Everolimus1 (2)1 (100)00
 Sirolimus1 (2)001 (100)
MMF2 (3)001 (100)
Steroid1 (2)1 (100)00
Two or more agents
CNIs+MMF21 (37)7 (33)6 (29)8 (38)
 CNIs51
 MMF17
CNIs+mTORi3 (5)1 (33.3)1 (33.3)1 (33.3)
 CNIs10
 mTORi01
CNIs+steroids9 (16)1 (11.2)4 (44.4)4 (44.4)
 CNIs44
 Steroids00
CNIs+AZA1 (2)1 (100)00
mTORi +MMF2 (3)1 (50)01 (50)
 mTOR01
 MMF00
  • AZA, azathioprine; CNIs, calcineurin inihibitors, including cyclosporine and tacrolimus; MMF, mycophenolate mofetil; mTORi, mammalian target of rapamycin inhibitor, including sirolimus and everolimus.